Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue
Mandate

Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue

September 03, 2021 M&A Capital Markets and Public M&A EU, Competition and Regulatory

Vinge has advised Irisity AB (publ) in connection with its acquisition of all shares in the Israeli company Agent Video Intelligence Ltd for a purchase price of approximately SEK 580 million.

The purchase price shall be paid in cash, and in part by way of newly issued shares in Irisity. Closing is subject to a resolution adopted at Irisity’s extraordinary general meeting to authorise the board of directors to adopt a resolution concerning a non-cash issue.

In connection with the closing of the transaction, Vinge advised Irisity regarding a directed share issue that was performed as an accelerated bookbuilding arranged by Erik Penser Bank at a subscription price of SEK 49. Irisity received SEK 130 million before issue costs.

Vinge’s team consisted of Anders Strid, Anna Ståhlklo (M&A), Edin Agic (ECM) and Adrian Filipovic (ECM). S. Horowitx&Co acted as legal counsel in Israel in connection with the acquisition.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025